Skip to main content

Table 5 One-way sensitivity analyses

From: Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

Analysis

QALYs

Total costs

Cost per QALY

QALYs

Total costs

Cost per QALY

 

Patients with MMSE 10-26: donepezil versus no treatment

 

Patients with MMSE 10-20: donepezil versus memantine

 

Base Case

0.146

-€9,893

Dominant

0.017

-€2,825

Dominant

Caregiver Time Effects of Disease Severity ↓ 25%†

0.146

-€9,171

Dominant

0.017

-€2,608

Dominant

Patient Care Cost ↓ 25%‡

0.146

-€6,911

Dominant

0.017

-€2,417

Dominant

Patients institutionalized ↓ 25%

0.135

-€9,893

Dominant

0.015

-€2,825

Dominant

Patient Utility Effects of Disease Severity ↓ 25%

0.124

-€9,893

Dominant

0.015

-€2,825

Dominant

Stop Treatment if MMSE < 10

0.132

-€11,006

Dominant

0.018

-€2,279

Dominant

Stop Treatment if MMSE Deteriorates on any Scale after 6 Months

0.140

-€9,691

Dominant

0.054

-€4,578

Dominant

5 Year Time Horizon

0.140

-€10,172

Dominant

0,016

-€2,578

Dominant

Treatment Effects ↓ 25%†

0.107

-€5,930

Dominant

0.023

-€3,379

Dominant

No Discontinuation

0.204

-€13,215

Dominant

0.041

-€4,301

Dominant

Double Discontinuation

0.106

-€7,412

Dominant

0.003

-€1,760

Dominant

Treatment Duration 5 Years

0.140

-€10,171

Dominant

0.016

-€2,580

Dominant

Treatment Duration 1 Year

0.042

-€2,704

Dominant

0.008

-€991

Dominant

Alternative caregiver time effect (German data)[47]

0.146

-€16,677

Dominant

0.017

-€3,288

Dominant

Alternate disease severity definition based on German convention MMSE ranges *

0.151

-€9,486

Dominant

0.019

-€3,448

Dominant

  1. † Coefficients in regression equations relating to disease severity (MMSE, NPI, ADL, and IADL) were reduced by 25%
  2. ‡ All patient care costs were reduced by 25%
  3. * Mild MMSE ≥ 18, moderate MMSE 10-17, severe MMSE < 10